KR910019617A - 뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6- 테트라히드로피리딘의 용도 - Google Patents

뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6- 테트라히드로피리딘의 용도 Download PDF

Info

Publication number
KR910019617A
KR910019617A KR1019910008272A KR910008272A KR910019617A KR 910019617 A KR910019617 A KR 910019617A KR 1019910008272 A KR1019910008272 A KR 1019910008272A KR 910008272 A KR910008272 A KR 910008272A KR 910019617 A KR910019617 A KR 910019617A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
compound
neuronal
animal
brain
Prior art date
Application number
KR1019910008272A
Other languages
English (en)
Other versions
KR0181330B1 (ko
Inventor
프랑소와 쟈비에 꼬드
쟈끌린 프르니예
움베르또 구지
Original Assignee
원본미기재
소시에떼아노님 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 소시에떼아노님 사노피 filed Critical 원본미기재
Publication of KR910019617A publication Critical patent/KR910019617A/ko
Application granted granted Critical
Publication of KR0181330B1 publication Critical patent/KR0181330B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음

Description

뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 하기 일반식(I)의 적어도 하나의 화합물 또는 약제학적으로 허용가능한 그의 산 부가염을 예방학적 및/또는 치료학적 유효량으로 함유하는 뉴우런 변성 과정의 예방 및/또는 치료용 약제학적 조성물.
  2. 제1항에 있어서, 뉴우런 변성 과정이 기억력 손상, 혈관 치매증, 후-뇌염 장애, 후-졸증 장해, 뇌 손상으로 인한 후-외상성 증후군, 뇌 산소 결핍증, 알쯔하이머병, 노인성 치매증, 헌팅론 무드병 및 파킨슨 증후군과 같은 피질 하부 치매중, AIDS치매증, 교감신경 또는 지각 신경의 괴사 또는 손상에 의해 유발되는 신경병, 뇌부종, 및 척수소뇌 변성을 포함하는 약제학적 조성물.
  3. 제1항에 있어서, 일반식(I)의 화합물이 1-[2-(2-나프틸) 에틸]-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피린딘 또는 약제학적으로 허용가능한 그의 염인 약제학적 조성물.
  4. 제1항 내지 3항중 어느 한항에 있어서, 단위 투여 형태임을 특징으로 하는 약제학적 조성물.
  5. 제4항에 있어서, 단위 투여량이 2~300mg의 활성원을 함유하는 약제학적조성물.
  6. 제5항에 있어서, 단위 투여량이 5~150mg의 활성원을 함유하는 약제학적 조성물.
  7. 제6항에 있어서, 단위 투여량이 5~50mg의 활성원을 함유하는 약제학적 조성물.
  8. -동물의 내격막에서 손상을 유발하기 위해 유효한 양의 빈크리스틴을 주사함으로써 실험동물의 뉴우런을 손상시키고, -적절히 선택된 계획에 따라 시험하고자 하는 화합물을 손상된 동물에 투여하며, -공지의 형태학적/생화학적 및/또는 행동 분석에 의해 시험 화합물의 효과를 평가하는것으로 구성된 뉴우런 활성 화합물의 약리학적 선별 방법.
  9. 뉴우런 손상을 위해 유효한 양의 빈크리스틴을 실험 동물의 내격막에 주사함을 포함하는 실험 동물에게 뉴우런 손상을 유발하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910008272A 1990-05-22 1991-05-22 뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의 용도 KR0181330B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9006399 1990-05-22
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (2)

Publication Number Publication Date
KR910019617A true KR910019617A (ko) 1991-12-19
KR0181330B1 KR0181330B1 (ko) 1999-03-20

Family

ID=9396855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008272A KR0181330B1 (ko) 1990-05-22 1991-05-22 뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6-테트라히드로피리딘의 용도

Country Status (17)

Country Link
US (3) US5229389A (ko)
EP (2) EP0458696B1 (ko)
JP (2) JP2618115B2 (ko)
KR (1) KR0181330B1 (ko)
AT (2) ATE132369T1 (ko)
BR (1) BR9105015A (ko)
CA (2) CA2365832C (ko)
CY (1) CY2283B1 (ko)
DE (2) DE69115989T2 (ko)
DK (2) DK0458696T3 (ko)
FR (1) FR2662355B1 (ko)
HK (1) HK1001471A1 (ko)
HU (1) HU208922B (ko)
IE (1) IE911707A1 (ko)
IL (3) IL112167A (ko)
TW (1) TW216771B (ko)
ZA (1) ZA913865B (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
ATE200423T1 (de) * 1995-10-26 2001-04-15 Sanofi Synthelabo Verwendung von 1-(2-naphtylethyl)-4-(3- trifluoromethylphenyl)-1,2,3,6-tetrahydropyridi zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
AU719038B2 (en) * 1996-03-29 2000-05-04 Trustees Of Boston University Methods for diagnosing and treating Alzheimer's disease
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) * 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
EE9900332A (et) * 1997-02-03 2000-02-15 Sanofi-Synthlabo 1-[4-(3-trifluorometüülfenüül)-1,2,3,6-tetrahüdropüriid-1-üül]-2-(6,7-dimetoksünaft-2- üül)etaani kasutamine neurotroopse toimega ravimite valmistamiseks
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
AU7713391A (en) 1991-11-28
TW216771B (ko) 1993-12-01
HK1001471A1 (en) 1998-06-19
IL112167A (en) 1996-01-31
DE69132797T2 (de) 2002-05-29
DK0458696T3 (da) 1996-05-20
CA2365832A1 (en) 1991-11-23
KR0181330B1 (ko) 1999-03-20
EP0458696B1 (fr) 1996-01-03
IL98175A (en) 1996-01-19
EP0458696A3 (en) 1992-03-18
JP2954029B2 (ja) 1999-09-27
DE69115989T2 (de) 1996-08-22
DE69115989D1 (de) 1996-02-15
HU911729D0 (en) 1991-12-30
DE69132797D1 (de) 2001-12-06
CY2283B1 (en) 2003-07-04
US5270320A (en) 1993-12-14
FR2662355B1 (fr) 1994-11-10
HUT59824A (en) 1992-07-28
ATE207747T1 (de) 2001-11-15
DK0655247T3 (da) 2002-02-18
ZA913865B (en) 1992-02-26
JPH04226917A (ja) 1992-08-17
EP0655247B1 (fr) 2001-10-31
IE20011078A1 (en) 2002-03-20
BR9105015A (pt) 1993-05-25
US5468753A (en) 1995-11-21
EP0458696A2 (fr) 1991-11-27
ATE132369T1 (de) 1996-01-15
JPH09132535A (ja) 1997-05-20
IL112167A0 (en) 1995-03-15
FR2662355A1 (fr) 1991-11-29
CA2042974C (en) 2002-09-17
HU208922B (en) 1994-02-28
AU636488B2 (en) 1993-04-29
US5229389A (en) 1993-07-20
CA2042974A1 (en) 1991-11-22
EP0655247A1 (fr) 1995-05-31
CA2365832C (en) 2007-08-07
IL98175A0 (en) 1992-06-21
JP2618115B2 (ja) 1997-06-11
IE911707A1 (en) 1991-12-04

Similar Documents

Publication Publication Date Title
KR910019617A (ko) 뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6- 테트라히드로피리딘의 용도
Harkany et al. β-Amyloid (Phe (SO3H) 24) 25–35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation
Sachdev et al. Role of the basal forebrain cholinergic projection in somatosensory cortical plasticity
JP7082186B2 (ja) プリドピジンによる筋萎縮性側索硬化症の治療方法
DE1620608B2 (de) N-substltuierte Lactame und Verfahren zu ihrer Herstellung
Shoykhet et al. Whisker trimming begun at birth or on postnatal day 12 affects excitatory and inhibitory receptive fields of layer IV barrel neurons
DE69825605T2 (de) Behandlung der schizophrenie und der psychose
Wauquier et al. A comparison between astemizole and other antihistamines on sleep-wakefulness cycles in dogs
Ramanathan et al. Cholinergic systems are essential for late-stage maturation and refinement of motor cortical circuits
EP1707202A1 (de) Organische Verbindungen
Konduru et al. Sleep‐wake characteristics in a mouse model of severe traumatic brain injury: Relation to posttraumatic epilepsy
CN110612102A (zh) 含有吡唑并喹啉衍生物的路易氏体病治疗剂
Ding et al. Foramen lacerum impingement of trigeminal nerve root as a rodent model for trigeminal neuralgia
DE60128911T2 (de) Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen
Handwerker et al. Pain models: translational relevance and applications
Oleson et al. Effects of the histamine H1 receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward
DE69907220T2 (de) Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
DE69127285T2 (de) Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen
Hajnik et al. Sleep loss and recovery after administration of drugs related to different arousal systems in rats
DE69911373T2 (de) Azetidincarboxamidderivate zur behandlung von zns-erkrankungen
DE69710526T2 (de) Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen
Rucker et al. Discriminative conditioning-related slow potential and single-unit responses in the frontal cortex of urethane-anesthetized rats
DE69421705T2 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
Ishii et al. Effects of moguisteine on the cough reflex induced by afferent electrical stimulation of the superior laryngeal nerve in guinea pigs
RU2301065C2 (ru) Новое применение илоперидона

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101124

Year of fee payment: 13

EXPY Expiration of term